Therapeutic Programs

Glioblastoma program: current imaging and dosimetry step

Glioblastoma is Curasight’s lead therapeutic development program. The current Phase 1 human study uses 64Cu-DOTA-AE105 at imaging and dosimetry activity together with regional super-selective intra-arterial cerebral administration to evaluate delivery, biodistribution and dosimetry.

Preliminary company-reported findings from the current study are intended to inform whether the regional delivery approach and resulting biodistribution support progression to therapeutic dosing.

Glioblastoma program: 177Lu uTREAT® therapeutic path

Following the current 64Cu imaging and dosimetry study, Curasight is preparing a 177Lu uPAR-targeted therapeutic product within uTREAT® for a subsequent dose-finding and phase 2 study in glioblastoma subject to successful development, regulatory approval and the supporting human dosimetry data.

Next-generation ligand drives additional therapeutic programs

In parallel, Curasight is advancing a next-generation uPAR-targeting ligand within the uTREAT® platform for radioligand therapy across selected solid tumors. The ligand architecture is designed to support separate radionuclide-specific product candidates, including alpha- and beta-emitting products where tumor biology and dosimetry support their use. Candidate selection considers binding, stability, biodistribution, dosimetry and manufacturability.